Why is Novelix Pharmaceuticals Ltd ?
1
Poor Management Efficiency with a low ROE of 2.18%
- The company has been able to generate a Return on Equity (avg) of 2.18% signifying low profitability per unit of shareholders funds
2
Company has a low Debt to Equity ratio (avg) at 0.01 times
3
Healthy long term growth as Net Sales has grown by an annual rate of 164.02%
4
With a growth in Operating Profit of 63.08%, the company declared Very Positive results in Sep 26
- The company has declared positive results for the last 6 consecutive quarters
- ROCE(HY) Highest at 8.00%
- NET SALES(Q) At Rs 44.73 cr has Grown at 21.8% (vs previous 4Q average)
- PBDIT(Q) Highest at Rs 2.12 cr.
5
Technical trend is Sideways signifying no clear price momentum
- The technical trend has improved from Mildly Bearish on 18-Nov-26 and has generated -0.65% returns since then
6
With ROE of 7.1, it has a Fair valuation with a 2.8 Price to Book Value
- The stock is trading at a premium compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 8.39%, its profits have risen by 368% ; the PEG ratio of the company is 0.3
How much should you hold?
- Overall Portfolio exposure to Novelix Pharma. should be less than 10%
- Overall Portfolio exposure to Retailing should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Retailing)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Novelix Pharma. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Novelix Pharma.
8.39%
0.14
59.44%
Sensex
-2.0%
-0.13
14.98%
Quality key factors
Factor
Value
Sales Growth (5y)
164.02%
EBIT Growth (5y)
28.95%
EBIT to Interest (avg)
0.77
Debt to EBITDA (avg)
1.17
Net Debt to Equity (avg)
0.05
Sales to Capital Employed (avg)
1.48
Tax Ratio
15.27%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
-2.43%
ROE (avg)
2.18%
Valuation Key Factors 
Factor
Value
P/E Ratio
40
Industry P/E
40
Price to Book Value
2.85
EV to EBIT
33.04
EV to EBITDA
31.50
EV to Capital Employed
2.76
EV to Sales
1.22
PEG Ratio
0.28
Dividend Yield
NA
ROCE (Latest)
8.34%
ROE (Latest)
7.12%
Loading Valuation Snapshot...
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
No Trend
Mildly Bearish
Technical Movement
21What is working for the Company
ROCE(HY)
Highest at 8.00%
NET SALES(Q)
At Rs 44.73 cr has Grown at 21.8% (vs previous 4Q average
PBDIT(Q)
Highest at Rs 2.12 cr.
PBT LESS OI(Q)
Highest at Rs 1.87 cr.
PAT(Q)
Highest at Rs 1.56 cr.
-1What is not working for the Company
DEBTORS TURNOVER RATIO(HY)
Lowest at 1.47 times
Loading Valuation Snapshot...
Here's what is working for Novelix Pharma.
Net Sales - Quarterly
At Rs 44.73 cr has Grown at 21.8% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 36.72 CrMOJO Watch
Near term sales trend is positive
Net Sales (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 2.12 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 1.87 cr.
in the last five quartersMOJO Watch
Near term PBT trend is positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
Highest at Rs 1.56 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Here's what is not working for Novelix Pharma.
Debtors Turnover Ratio- Half Yearly
Lowest at 1.47 times
in the last five half yearly periodsMOJO Watch
Company's pace of settling its Debtors has slowed
Debtors Turnover Ratio